...a patient subgroup that was more responsive to treatment. The Phase IV IMIOXC study tested oxcarbazepine...
...sensory function -- the “irritable nociceptor phenotype” -- would be more likely to respond to oxcarbazepine...
...organizing principle based on sensory profiles.” Pain (2017) Demant, D., et al. “The effect of oxcarbazepine...

...and 7,910,131 by submitting an ANDA to FDA for a generic version of Oxtellar XR oxcarbazepine...

...U.S. District Court for the District of New Jersey against Actavis regarding Supernus' Oxtellar XR oxcarbazepine...
...which expires on Oct. 29, 2015. In February, Supernus launched the once-daily extended-release formulation of oxcarbazepine...

...that Actavis submitted an ANDA to FDA for a generic version of Supernus' Oxtellar XR oxcarbazepine...
...that expires on Oct. 29, 2015. In February, Supernus launched the once-daily extended-release formulation of oxcarbazepine...

...sale of convertible senior secured notes due 2019. Earlier this year, Supernus launched Oxtellar XR oxcarbazepine...

...at $5.30. Supernus proposed the offering late Wednesday. Earlier this year, Supernus launched Oxtellar XR oxcarbazepine...
...adults and children ages 6-17 years old. The product is a once-daily extended-release formulation of oxcarbazepine...

...investors of convertible senior secured notes due 2019. Earlier this year, Supernus launched Oxtellar XR oxcarbazepine...
...adults and children ages 6-17 years old. The product is a once-daily extended-release formulation of oxcarbazepine...

...Brasil Farmaceutica Ltda. Brazilian subsidiary will market Ranbaxy's branded antiepileptic generics Bipogine lamotrigine and Selzic oxcarbazepine...

...Supernus launched Oxtellar XR oxcarbazepine in the U.S. as an adjunctive therapy in the treatment of...
...wholesale acquisition cost for a pack of 100 tablets of the once-daily extended-release formulation of oxcarbazepine...